Alternative Immunotherapy Drug More Effective than Current Standard of Care in Treating Advanced Melanoma after Surgical Removal of Disease


The immunotherapy drug nivolumab is safer and more effective than ipilimumab–the current standard of care–in treating patients with resected stage III and stage IV melanoma.